Canagliflozin hemihydrate (also known as TA-7284; JNJ-24831754ZAE; JNJ 28431754AAA; JNJ-28431754; Invokana), the hemihydrated form of Canagliflozin, is a highly potent and selective SGLT2 inhibitor with anti-diabetic effects.
Ipragliflozin (also known as ASP1941) is a novel, highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) with IC50 value of 7.4 nM for hSGLT2.
Tofogliflozin (also known as CSG-452) hydrate is a novel, very potent and highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2) with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse respectively.
Ertugliflozin (formerly known as PF04971729; PF-04971729; trade name: Steglatro) is an orally bioactive and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with hypoglycemic and antidiabetic activity.
Dapagliflozin impurity is an isomer of Dapagliflozin which is a SGLT2 (sodium-glucose transporter 2) inhibitor approved in 2012 for the treatment of type 2 diabetes.
Tofogliflozin (also known as CSG-452) hydrate is a novel, very potent and highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2) with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse respectively.
Ertugliflozin pidolate (formerly known as also known as PF-04971729; trade name: Steglatro), the pidolate salt of ertugliflozin, is a potent, orally bioavailable and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2)approved in 2017 by FDA for treating type 2 diabetes mellitus.
Licogliflozin (LIK066) is a novel, potent and orally bioavailable dual inhibitor of sodium-glucose transporter-1 (SGLT1) and sodium-glucose transporter-2 (SGLT2), with an in vivo inhibitory concentration (IC50) of 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2.
Canagliflozin D4 is the tetra-deuterated form of Canagliflozin (TA-7284; JNJ-24831754ZAE; JNJ 28431754-AAA; JNJ-28431754; Invokana) which is a selective SGLT2 inhibitor approved by FDA for the treatment of type 2 diabetes.
Bexagliflozin (formerly known as THR 1442; EGT1442; EGT-1442; Brenzavvy) is a potent and selective SGLT2 inhibitor with antidaibetic activity.